A comparative study to determine outcome of Metformin and Myoinositol in women with Polyendocrine Metabolic Ovarian Syndrome

INTERVENTION: Control Intervention1: Dr. Shivangee Lomesh: Junior Resident, department of pharmacology, DMC and H, Ludhiana CONDITION: Health Condition 1: E282‐ Polycystic ovarian syndrome PRIMARY OUTCOME: 1.Mean change in HOMA IRTimepoint: measurement to be taken at the time of enrollment. follow up will be done at 3 months and at 6 months SECONDARY OUTCOME: 1. Changes in the LAP in both groups. ; 2. Difference in the metabolic parameters , Total cholesterol, LDL, HDL, TG. ; 3. Menstrual cycle regularity. ; 4. Incidence of ADRs. ; 5. Changes in modified Ferriman Gallwey score ,Annexure A ; 6. Change in acne score ,Annexure B ; 7. Changes in PCOSQOL I score ,Annexure C ; Timepoint: measurement to be taken at the time of enrollment follow up will be done at 3 months and at 6 months INCLUSION CRITERIA: 1. Women aged 18 to 40 years. 2. Diagnosed with PMOS according to Rotterdam criteria, 2003. 3. Willing to provide written informed consent.